Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTX-134 in Adults With Phenylketonuria
NCT04110496Phase 1Terminated
- Sponsor
- Rubius Therapeutics
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rtx-134 in phenylketonuria (PKU), sponsored by Rubius Therapeutics. Primary endpoints: Frequency of treatment emergent adverse events, Correlation of dose with percent reduction in serum phenylalanine levels and 3 more. Started Jan 2020; status: terminated.
02
Drugs
rtx-134
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT04110496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04110496.